- Robust manufacturing processes are needed to transform human health by cell therapies
- An ERC that engages stakeholders in fundamental multi-disciplinary team-oriented manufacturing research will transform the cell manufacturing industry
- MSCs, engineered T cells, and iPSC-derived cardiomyocyte testbeds represent current and future cell manufacturing process
- Synergistic thrusts will enable development of efficient, robust, scalable, cost-effective manufacturing of safe and potent cell therapies
- CMaT researchers are leaders of the field and are well-poised to thrive in cross-cutting integrative research
- CMaT students will comprise a diverse, highly-trained multidisciplinary workforce who will lead the revolution in cell therapy manufacturing
CMaT’s overall research plan and its impact on industry and workforce is shown below. This strategic plan is structured around a broad stakeholder‐driven ecosystem with three inter‐dependent and convergent Thrusts, and three industry‐relevant Test‐Beds (Engineered Systems) that are integrated and cross‐cutting across all three Thrust areas. As shown, CMaT will have tremendous impact in strengthening the nascent industry.
CMaT 3 Plane Chart
CMaT will employ broad, multi‐disciplinary SMART (Specific, Measurable, Adaptive and Achievable, Responsive and Realistic, and Transformative and Timely) strategies to gain fundamental knowledge, develop technologies, and overcome barriers identified in the NCMC Roadmap.
First, new knowledge will be gained to catapult scalable cell manufacturing, especially in areas of critical quality attributes (CQA), i.e., the properties or biomarkers of a given type of cell that “predict’ its safety, efficacy, or potency. The lack of reliable CQAs is major barrier in the success of cell therapies as well as their reproducibility across clinical centers and industry. There is also little correlation between in vitro and in vivo potency‐safety (i.e., quality) measurements. Furthermore, not much is known on how scaling of the manufacturing process affects cell function. In collaboration with NIST and the Standards Coordinating Body (SCB), we will use measurement science approaches in all aspects of cell characterization and process development, enabling standards development for the broader cell manufacturing industry. Second, CMaT will develop new enabling tools and technologies that would be broadly applicable to all Test‐Beds as well as other cell therapies and biomanufacturing platforms. Such tools and technologies include rapid, in‐line testing of critical cell attributes through multiplexed sensors and imaging probes; organ/disease‐on‐a‐chip models for rapid, low‐cost, potency testing; big‐data analytics to model cell quality; as well as engineered biomaterials and bioreactors coupled with advanced process modeling and supply chain innovation and integration. Third, at the Engineered Systems level, CMaT will address key barriers in each Test‐Bed: predicting safety and efficacy on industry relevant Test8 Strategic Plan Beds; large‐scale, low‐cost manufacturing; lack of industry standards and a trained workforce, and regulatory and social policy as related to large‐scale cell therapies. Finally, CMaT will nurture an inclusive, industry‐academia‐clinician‐government ecosystem to achieve its goals. This broad strategy, driven by needs from industry, academics, clinicians, patients, and regulatory agencies, will collectively enable large‐scale, low‐cost, reproducible manufacturing of high‐quality therapeutic cells.
Through these efforts, CMaT will reduce the cost, increase access to, and improve the efficacy and reproducibility of cell therapies, which will enable industry growth, alleviate patient suffering, improve the healthcare economy, and transform how we routinely treat incurable and chronic diseases.